TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32031904

Group type: EXPERIMENTAL
Intervention: HIV patients accessing antiretroviral treatment
Number of subjects: 200
Study: 35768650

Group type: EXPERIMENTAL
Intervention: guselkumab 100 mg every 4 weeks (Q4W)
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: guselkumab 100 mg at Week 0, Week 4, then every 8 weeks (Q8W)
Number of subjects: 381

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 381
Study: 33567129

Group type: EXPERIMENTAL
Intervention: Raltitrexed (3 mg/m2 from day 1 every 3 weeks) and oral S‐1 (80‐120 mg for 14 days every 3 weeks)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Raltitrexed combined with S-1 (RS regimen)
Number of subjects: 105
Study: 35666800

Group type: EXPERIMENTAL
Intervention: 0.9 mg of 0.1% E2 gel daily
Number of subjects: 78

Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 78
Study: 33152704

Group type: EXPERIMENTAL
Intervention: PET/CT
Number of subjects: 799

Group type: COMPARATOR
Intervention: SoC (CT CAP and bone scan)
Number of subjects: 799
Study: 35031887

Group type: EXPERIMENTAL
Intervention: Cocoa flavanols (415 mg)
Number of subjects: 80
Study: 34238546

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Haemodynamic therapy to achieve individualised preoperative DO2
Number of subjects: 35
Study: 35303025

Group type: EXPERIMENTAL
Intervention: Higher initial levels of shame
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Guilt
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Initial levels of guilt
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Higher initial levels of other drug use
Number of subjects: 110
Study: 32023543

Group type: EXPERIMENTAL
Intervention: Blood Flow Restriction (BFR) at 45% of resting pulse elimination pressure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control conditions (0% BFR)
Number of subjects: 0
Study: 33428581

Group type: EXPERIMENTAL
Intervention: E-learning module
Number of subjects: 75

Group type: COMPARATOR
Intervention: Traditional didactic video
Number of subjects: 75
Study: 32217524

Group type: EXPERIMENTAL
Intervention: Foot orthoses
Number of subjects: 218

Group type: COMPARATOR
Intervention: Hip exercises
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Foot orthoses (high midfoot width mobility)
Number of subjects: 218

Group type: COMPARATOR
Intervention: Hip exercises (high midfoot width mobility)
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Foot orthoses (low midfoot width mobility)
Number of subjects: 218

Group type: COMPARATOR
Intervention: Hip exercises (low midfoot width mobility)
Number of subjects: 218
Study: 34931479

Group type: EXPERIMENTAL
Intervention: ESAS-screened
Number of subjects: 119806

Group type: COMPARATOR
Intervention: Not screened (Control)
Number of subjects: 119806
Study: 34812863

Group type: EXPERIMENTAL
Intervention: Intra-articular Platelet-Rich Plasma (PRP) injections (n=144 participants)
Number of subjects: 288

Group type: COMPARATOR
Intervention: Saline placebo injections (n=144 participants)
Number of subjects: 288
Study: 34091814

Group type: EXPERIMENTAL
Intervention: INVOS 5100C (Medtronic, Minneapolis, MN, USA)
Number of subjects: 70

Group type: COMPARATOR
Intervention: FORE-SIGHT ELITE (CAS Medical Systems, Branford, CT, USA)
Number of subjects: 70
Study: 34475964

Group type: EXPERIMENTAL
Intervention: Qishen Yiqi dripping pills (QSYQ) for 12 weeks
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 66
Study: 35839499

Group type: EXPERIMENTAL
Intervention: Parallel processing for induction of anesthesia and OR cleaning with sugammadex
Number of subjects: 111

Group type: COMPARATOR
Intervention: Traditional linear processing for induction of anesthesia and OR cleaning with neostigmine/glycopyrrolate
Number of subjects: 111
Study: 33781280

Group type: EXPERIMENTAL
Intervention: Blueberry supplementation (BLU)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 11
Study: 32275024

Group type: EXPERIMENTAL
Intervention: Thoracic epidural (TEA) with 0.25% bupivacaine and continuous infusion of 0.1% bupivacaine with 2 mcg/ml of fentanyl.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intercostal block (ICN) with 0.25% bupivacaine and continuous intravenous morphine infusion of 0.015‐0.02 mg/kg/hr.
Number of subjects: 0
Study: 34501882

Group type: EXPERIMENTAL
Intervention: Multicomponent intervention including a Garmin watch, under-desk pedal machine, and management support
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Multicomponent intervention
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Focus groups for acceptability assessment
Number of subjects: 22
Study: 615918400

Group type: EXPERIMENTAL
Intervention: Cataract surgery in PEX group
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Cataract surgery in non-PEX group
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Cataract surgery in both groups
Number of subjects: 31
Study: 34839386

Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MedDiet) adherence
Number of subjects: 2278

Group type: EXPERIMENTAL
Intervention: Systolic blood pressure reduction
Number of subjects: 2278

Group type: EXPERIMENTAL
Intervention: Low density-lipoprotein cholesterol reduction
Number of subjects: 2278

Group type: EXPERIMENTAL
Intervention: Body weight reduction
Number of subjects: 2278
Study: 34020205

Group type: EXPERIMENTAL
Intervention: Active iTBS (1200 pulses per session, twice daily over ten weekdays)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Sham condition (magnetically shielded side of the coil and simultaneous transcutaneous electrical nerve stimulation)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Active iTBS
Number of subjects: 56

Group type: COMPARATOR
Intervention: Sham condition
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Overall depressive symptoms in patients with depression
Number of subjects: 56
Study: 32757049

Group type: EXPERIMENTAL
Intervention: Flumatinib mesylate after a high-fat diet
Number of subjects: 12

Group type: COMPARATOR
Intervention: Flumatinib mesylate in fasting state
Number of subjects: 12
Study: 35727095

Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg daily for 4 weeks followed by 40 mg for 8 weeks
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg for 4 weeks followed by 20 mg for 8 weeks
Number of subjects: 89
Study: 32716320

Group type: EXPERIMENTAL
Intervention: Pimavanserin 34 mg once daily
Number of subjects: 171

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171
Study: 35763324

Group type: EXPERIMENTAL
Intervention: Run4Love intervention (3-month program including cognitive behavioral stress management and exercise promotion via WeChat)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Usual care and a brochure on nutrition (control group)
Number of subjects: 300
Study: 34483780

Group type: EXPERIMENTAL
Intervention: MRI image analysis based on variable model algorithm
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Variable model improvement algorithm
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: MRI images based on variable model algorithm
Number of subjects: 100
Study: 34314906

Group type: EXPERIMENTAL
Intervention: 8 mg intravenous ondansetron
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 3 mg intravenous granisetron
Number of subjects: 120

Group type: COMPARATOR
Intervention: 10 ml normal saline (placebo)
Number of subjects: 120
Study: 32585185

Group type: EXPERIMENTAL
Intervention: Counsellor-led problem-solving intervention with supporting printed materials
Number of subjects: 251

Group type: COMPARATOR
Intervention: Printed booklets alone (control group)
Number of subjects: 251
Study: 34669209

Group type: EXPERIMENTAL
Intervention: Inebilizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 32736460

Group type: EXPERIMENTAL
Intervention: Upper partial J‐shaped sternotomy
Number of subjects: 112

Group type: COMPARATOR
Intervention: Median sternotomy
Number of subjects: 112
Study: 35658022

Group type: EXPERIMENTAL
Intervention: Dulaglutide 0.75 mg
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Dulaglutide 1.5 mg
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Pooled Dulaglutide groups
Number of subjects: 154

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Dulaglutide
Number of subjects: 154
Study: 35246123

Group type: EXPERIMENTAL
Intervention: Biologics (mepolizumab, benralizumab, dupilumab)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135
Study: 34528335

Group type: EXPERIMENTAL
Intervention: Endovascular treatment (EVT) referral volume from PSCs
Number of subjects: 1541
Study: 32363529

Group type: EXPERIMENTAL
Intervention: Linked Color Imaging (LCI) + White Light Imaging (WLI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: White Light Imaging (WLI)
Number of subjects: 0
Study: 33419469

Group type: EXPERIMENTAL
Intervention: New experimental therapy
Number of subjects: 1516

Group type: COMPARATOR
Intervention: Original experimental arm
Number of subjects: 1516

Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 1516
Study: 32969541

Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive-behavioral therapy (ICBT)
Number of subjects: 301

Group type: COMPARATOR
Intervention: Face-to-face cognitive-behavioral therapy (CBT)
Number of subjects: 301
Study: 34397805

Group type: EXPERIMENTAL
Intervention: PVI + CFAE
Number of subjects: 50

Group type: COMPARATOR
Intervention: PVI only
Number of subjects: 50
Study: 32936680

Group type: EXPERIMENTAL
Intervention: Dehydration (24-h fluid restriction, USG>1.020) in men
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Dehydration (24-h fluid restriction, USG>1.020) in women (FDehy)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Dehydration (24-h fluid restriction, USG>1.020) in women (LDehy)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Euhydrated condition (USG<1.020) in men
Number of subjects: 22

Group type: COMPARATOR
Intervention: Euhydrated condition (USG<1.020) in women (FDehy)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Euhydrated condition (USG<1.020) in women (LDehy)
Number of subjects: 22
Study: 35357107

Group type: EXPERIMENTAL
Intervention: Apple
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Honey
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pure fructose powder
Number of subjects: 0
Study: 32743954

Group type: EXPERIMENTAL
Intervention: Prucalopride 4 mg daily
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 36397397

Group type: EXPERIMENTAL
Intervention: Peripheral patellar denervation (PD)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Patellar resurfacing (PR)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Simple TKA (Control group)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: All groups (PD, PR, and Control)
Number of subjects: 202
Study: 32162274

Group type: EXPERIMENTAL
Intervention: Remogliflozin etabonate 100 mg BID
Number of subjects: 612

Group type: EXPERIMENTAL
Intervention: Remogliflozin etabonate 250 mg BID
Number of subjects: 612

Group type: COMPARATOR
Intervention: Dapagliflozin 10 mg QD
Number of subjects: 612

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 612
Study: 35136294

Group type: EXPERIMENTAL
Intervention: Thulium fiber laser (TFL)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Holmium laser
Number of subjects: 125
Study: 35430192

Group type: EXPERIMENTAL
Intervention: Significant valvular dysfunction
Number of subjects: 189

Group type: COMPARATOR
Intervention: No significant valvular dysfunction (comparator group)
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Aortic stenosis
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Mitral regurgitation
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Valvular disease
Number of subjects: 189
Study: 34387101

Group type: EXPERIMENTAL
Intervention: Increased mean heart rate (HR)
Number of subjects: 994

Group type: EXPERIMENTAL
Intervention: Heart rate average real variability (HR-ARV)
Number of subjects: 994

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 994
Study: 32856041

Group type: EXPERIMENTAL
Intervention: Functional Restoration Program (FRP)
Number of subjects: 32
Study: 36170688

Group type: EXPERIMENTAL
Intervention: High-dose glucocorticoids (methylprednisolone 10 mg/kg)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Low-dose glucocorticoids (dexamethasone 8 mg)
Number of subjects: 25
Study: 32807666

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBOT)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control
Number of subjects: 24
Study: 33736734

Group type: EXPERIMENTAL
Intervention: Working in COVID-19 wards
Number of subjects: 3421

Group type: EXPERIMENTAL
Intervention: Working in non-COVID-19 geriatrics and rehabilitation wards
Number of subjects: 3421

Group type: COMPARATOR
Intervention: Office workers
Number of subjects: 3421

Group type: EXPERIMENTAL
Intervention: Nursing assistants
Number of subjects: 3421

Group type: EXPERIMENTAL
Intervention: Use of public transportation
Number of subjects: 3421

Group type: EXPERIMENTAL
Intervention: Community exposure to SARS-CoV-2
Number of subjects: 3421

Group type: EXPERIMENTAL
Intervention: Working in a ward with a nosocomial COVID outbreak
Number of subjects: 3421

Group type: EXPERIMENTAL
Intervention: Use of respirators
Number of subjects: 3421
Study: 32068442

Group type: EXPERIMENTAL
Intervention: Glucose ingestion
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Fat ingestion
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Protein ingestion
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control subjects (non-operated)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Orlistat® with fat ingestion
Number of subjects: 10
Study: 35960850

Group type: EXPERIMENTAL
Intervention: Weight management program 'ShipShape'
Number of subjects: 178
Study: 34592180

Group type: EXPERIMENTAL
Intervention: ramucirumab
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: merestinib
Number of subjects: 309

Group type: COMPARATOR
Intervention: pooled placebo
Number of subjects: 309
Study: 32149863

Group type: EXPERIMENTAL
Intervention: Conditioning with continuous reinforcement (CRF)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Conditioning with partial reinforcement (PRF)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Counterconditioning
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Extinction
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Conditioning with PRF
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Conditioning with CRF
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: CRF and PRF
Number of subjects: 140

Group type: COMPARATOR
Intervention: Sham-conditioning control group
Number of subjects: 140
Study: 34193224

Group type: EXPERIMENTAL
Intervention: EIT group (individualized PEEP based on ventilation distribution)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Control group (low PEEP/FiO2 table)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: EIT group
Number of subjects: 117

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 117
Study: 34953166

Group type: EXPERIMENTAL
Intervention: Brief video on health harms of WTS
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Brief video on overcoming myths about WTS
Number of subjects: 238

Group type: COMPARATOR
Intervention: No video (Control)
Number of subjects: 238
Study: 32809976

Group type: EXPERIMENTAL
Intervention: HRZE treatment
Number of subjects: 69

Group type: COMPARATOR
Intervention: Ineffective therapy
Number of subjects: 69
Study: 33221378

Group type: EXPERIMENTAL
Intervention: Growth factors (specific types not mentioned)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ERBB–RAS–MAPK signal transduction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Statistical analyses of single-cell responses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Comparison of true and randomized datasets
Number of subjects: 0
Study: 32197616

Group type: EXPERIMENTAL
Intervention: Pre-consultation testing
Number of subjects: 878

Group type: COMPARATOR
Intervention: Standard practices (control)
Number of subjects: 878
Study: 34922193

Group type: EXPERIMENTAL
Intervention: 5% additional loading of individual body mass
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Higher loading conditions
Number of subjects: 14
Study: 34444949

Group type: EXPERIMENTAL
Intervention: Oat beta-glucans with high molar mass, used for 30 days
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Oat beta-glucans with low molar mass, used for 30 days
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 48
Study: 32748293

Group type: EXPERIMENTAL
Intervention: Clazosentan (20 mg/h i.v. for 3 h)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Clazosentan (60 mg/h i.v. for 3 h)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Moxifloxacin (single oral dose of 400 mg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo (i.v. for 6 h)
Number of subjects: 36
Study: 34040198

Group type: EXPERIMENTAL
Intervention: Low-GI dietary advice
Number of subjects: 571

Group type: COMPARATOR
Intervention: Usual antenatal care
Number of subjects: 571
Study: 33957025

Group type: EXPERIMENTAL
Intervention: 1.0% hydrogen peroxide mouthwash and 0.5% hydrogen peroxide nasal spray for 7 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 40
Study: 35848045

Group type: EXPERIMENTAL
Intervention: Robot‐assisted mirror therapy (RMT)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard mirror therapy (MT)
Number of subjects: 24
Study: 33676601

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg once every 3 weeks for 35 cycles
Number of subjects: 622

Group type: COMPARATOR
Intervention: Chemotherapy (capecitabine, eribulin, gemcitabine, or vinorelbine)
Number of subjects: 622

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 622

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 622
Study: 35718575

Group type: EXPERIMENTAL
Intervention: Levetiracetam
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Valproate
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Fosphenytoin
Number of subjects: 249
Study: 32731829

Group type: EXPERIMENTAL
Intervention: Incisional negative-pressure wound therapy (iNPWT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard dressing
Number of subjects: 0
Study: 34618367

Group type: EXPERIMENTAL
Intervention: Topical Cyperus rotundus essential oil (CREO)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Hydroquinone (HQ)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Placebo (cold cream)
Number of subjects: 153
Study: 34727422

Group type: EXPERIMENTAL
Intervention: Ketamine (n=39)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Midazolam (n=39)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Open ketamine (for midazolam nonremitters)
Number of subjects: 78
Study: 35421836

Group type: EXPERIMENTAL
Intervention: VISIT tool (intervention)
Number of subjects: 246

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 246
Study: 34316231

Group type: EXPERIMENTAL
Intervention: Intrauterine administration of 500 IU hCG (0.5 ml) before IUI
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group received 0.5 ml of normal saline before IUI
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 200
Study: 35244365

Group type: EXPERIMENTAL
Intervention: Home-based balance training combined with pulmonary rehabilitation (PR-BT)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Home-based pulmonary rehabilitation (PR)
Number of subjects: 48
Study: 34414368

Group type: EXPERIMENTAL
Intervention: QazCovid-in® vaccine (5 μg each, two doses, administered intramuscularly, 21 days apart)
Number of subjects: 244

Group type: COMPARATOR
Intervention: Placebo (0.9% NaCl)
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: QazCovid-in® vaccine (one dose on day 1)
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: QazCovid-in® vaccine (two doses on day 1 and 21)
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: QazCovid-in® vaccine (two doses on day 1 and 21) for subjects aged ≥50 years
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: QazCovid-in® vaccine (one dose on day 1) for subjects aged ≥50 years
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: QazCovid-in® vaccine (after second dose)
Number of subjects: 244
Study: 35035473

Group type: EXPERIMENTAL
Intervention: Low-frequency rTMS over contralesional M1 (1 Hz) followed by 30 minutes of motor task practice (10 sessions within 2 weeks)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sham rTMS followed by the same motor task practice
Number of subjects: 24
Study: 34765666

Group type: EXPERIMENTAL
Intervention: Nx4 (Neurexan®)
Number of subjects: 45
Study: 33097947

Group type: COMPARATOR
Intervention: Fish oil (2000 mg/d DHA + 400 mg/d EPA)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Curcumin (160 mg/d)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Combination of fish oil and curcumin
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 33737025

Group type: EXPERIMENTAL
Intervention: Apixaban 2.5 mg twice daily for extended thromboprophylaxis (ETP) after radical cystectomy
Number of subjects: 72
Study: 33006618

Group type: EXPERIMENTAL
Intervention: No CMF group (breastfeeding without cow's milk formula)
Number of subjects: 312

Group type: COMPARATOR
Intervention: CMF group (breastfeeding supplemented with cow's milk formula)
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: No CMF group (with vitamin D levels above median)
Number of subjects: 312

Group type: COMPARATOR
Intervention: CMF group (with vitamin D levels above median)
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: No CMF group (highest quartile of total IgE)
Number of subjects: 312

Group type: COMPARATOR
Intervention: CMF group (highest quartile of total IgE)
Number of subjects: 312
Study: 35441485

Group type: EXPERIMENTAL
Intervention: Comprehensive orthopedic care group (n=63) including preoperative psychological counseling and preventative risperidone
Number of subjects: 128

Group type: COMPARATOR
Intervention: Conventional orthopedic care group (n=65)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Comprehensive orthopedic care group (n=63)
Number of subjects: 128
Study: 33114457

Group type: EXPERIMENTAL
Intervention: Family-based mental health program, eight sessions, details on dosage and duration not specified.
Number of subjects: 0